The mitochondrial permeability transition is a widely studied, but poorly understood, phenomenon in mitochondrial bioenergetics. It has been recognised that this phenomenon is related to the opening of a protein pore in the inner mitochondrial membrane, and that opening of this pore is the cause of some forms of mitochondrial dysfunction. In this work, we propose that carvedilol, a multi-role cardioprotective compound, may act as an inhibitor of the high-conductance state of the mitochondrial permeability transition pore, a conclusion supported by the finding that carvedilol provides differential protection against mitochondrial swelling in sucrose and KCl-based media, and that it is unable to protect against calcium-induced depolarisation of the mitochondrial membrane. We also show that carvedilol inhibits the oxidation of mitochondrial thiol groups and that, beyond causing a slight depression of the membrane potential, it has no inhibitory effect on mitochondrial calcium uptake.
Introduction
One pillar of the chemiosmotic theory of energy transduction is the impermeability of the inner mitochondrial membrane to solutes that are not transported by natural mitochondrial carriers. This impermeability can be reversed by a phenomenon known as the 'mitochondrial Ž . permeability transition' MPT , caused by the formation of Ž a proteinaceous pore the mitochondrial permeability tran-. sition pore, MPTP , from several mitochondrial proteins Žfor reviews see Zoratti and Szabo, 1995; Vercesi et al., . 1997; Bernardi, 1999 . This sudden loss of membrane integrity is perhaps the greatest riddle in mitochondrial studies and is a controversial subject. Agents such as Ž . calcium and phosphate the most studied , pro-oxidants such as t-butylhydroperoxide, or thiol cross-linkers such as phenylarsine oxide are inducers of the MTP.
During events such as cardiac ischemiarreperfusion, cardiac mitochondria may suffer severe damage due not only to the increasing payload of oxidative injury but also to the cellular and mitochondrial accumulation of calcium Ž and phosphate Baker et al., 1988, Kristian and Siesjo, . 1996 . The role of the mitochondrial permeability transition pore in the reperfusion injury of the heart is well established and may be a determinant of the fate of the cell.
The physiology of the mitochondrial permeability transition pore has been described by some groups. The socalled Alow-conductanceB state is useful for releasing the calcium accumulated in the mitochondrial matrix and for keeping the mitochondrial transmembrane electric poten-Ž . tial DC within the normal range, avoiding membrane Ž hyperpolarisation Ichas et al., 1994 Ichas et al., , 1997 Ichas and . Mazat, 1998 . The observed DC flickering in single mitochondria is considered to be due to repeated stochastic 0014-2999r01r$ -see front matter q 2001 Elsevier Science B.V. All rights reserved.
Ž . PII: S 0 0 1 4 -2 9 9 9 0 1 0 0 7 4 5 -2 ( )opening and closing of the mitochondrial permeability Ž . transition pore Huser et al., 1998 . The transition to a Ahigh-conductanceB state depends on the saturation of calcium-binding sites and this state is also responsible for Ž a permanent ATP deficit, leading to cell necrosis Ichas . and Mazat, 1998 . ŽÄ w Ž .
x w Carvedilol 1-carbazolyl-4 -oxy -3-2-methoxyphe-.
x Ž .4. noxyethyl -amino -propanol-2 is clinically used for the treatment of congestive heart failure, mild to moderate Ž . hypertension and myocardial infarction Dunn et al., 1997 . Carvedilol competitively blocks b , b and a -adreno-1 2 1 ceptors, while displaying vasodilating properties. Its antioxidant activity, which is responsible for additional cardioprotective actions not shared by other b-adrenoceptor Ž . antagonists Yue et al., 1992a,b , has also been established.
The effects of carvedilol in ischemic heart disease may be due to the protection of mitochondrial function, for instance, by suppression of oxidative damage to mitochon-Ž . dria Moreno et al., 1998 or inhibition of the cardiac Ž . exogenous NADH dehydrogenase Oliveira et al., 2000a , an organospecific enzyme located in the inner mitochondrial membrane that has been proposed to be a powerful Ž . generator of the superoxide radical Nohl, 1987a,b . Carvedilol also displays a weak protonophoretic activity Ž . Oliveira et al., 2000b .
The aim of this study was to investigate the effects of carvedilol in the mitochondrial permeability transition induced by calciumrphosphate in rat heart mitochondria. To this purpose, we followed several events associated with the opening of the mitochondrial permeability transition pore.
Materials and methods

Materials
Carvedilol and BM910228 were obtained from Boeh-Ž . ringer Mannheim, Germany and prepared in dimethyl-Ž . sulfoxide DMSO . All other compounds were purchased Ž . from Sigma St. Louis, MO
Animals
Ž
. Male Wistar rats 250-300 g , housed at 22 q 28C under artificial light for 12-h lightrday cycle and with access to water and food ad libitum, were used throughout the experiments. The research reported here was carried out in accordance with the National Requirement for Vertebrate Animal Research.
Isolation of mitochondria from rat heart
Ž Rat heart mitochondria from male Wistar rats 250-300 . Ž g were prepared as previously described Oliveira et al., 2000a . Mitochondrial protein content was determined by the biuret method, calibrated with bovine serum albumin. and 1 mg of mitochondria. Energised mitochondria were Ž obtained with 8 mM succinate plus 4 mM rotenone and . 0.5 mg oligomycin . Carvedilol was pre-incubated with the mitochondrial suspension for 3 min before mitochondrial energisation.
Measurement of mitochondrial transmembrane potential
Determination of mitochondrial swelling
Changes in mitochondrial volume were followed by monitoring the classic decrease in absorbance at 540 nm with a Jasco V-560 spectrophotometer. The assays were performed in 2 ml of standard media with 4 mM rotenone, 0.5 mg oligomycin and 8 mM succinate and 1 mg protein.
In a separate set of experiments, 200 mM sucrose was replaced by 100 mM KCl or by a combination of either 100 mM polyethyleneglycol 200 or 1000 plus 60 mM KCl. Carvedilol was pre-incubated with the mitochondrial preparation for 3 min at 258C. In some experiments, simultaneous measurements of mitochondrial DC and swelling were obtained using a Spectronic 20 spectrophotometer and a TPP q -selective electrode immersed in 4 ml of the standard media and with 2 mg of mitochondrial protein.
Determination of mitochondria protein thiol content
To determine the antioxidant protective effect of carvedilol on thiol groups in sucrose and KCl-based media, Ž . we used a variation of Ellman's method Riddles, 1979 . After each incubation, two 0.75-ml samples were taken and added to 0.75 ml of sulphosalicilic acid 4% each and submitted to centrifugation at 15 500 g for 15 min in a Sigma 3K30 Centrifuge at 48C.
The supernatant was discarded and the pellet was suspended in 1.5 ml of phosphate buffer 100 mM, pH 8. The suspension was sonicated and a 1.0-ml sample was diluted to 2.6 ml in phosphate buffer medium containing 385 mM dithionitrobenzoic acid. The absorption was measured at 412 nm. 
Calcium accumulation by heart mitochondria
The Ca 2q storage capacity of mitochondria was estimated spectrophotometrically at 660 nm in a Jasco 560 Ž spectrophotometer, as described Solem and Wallace, . 1993 . Mitochondria were suspended at 0.25 mgrml in 2 ml of medium added to a cuvette maintained at 258C. After 2q Ž . 1 min, Ca was added 200-300 nmol , and mitochondria were energised with 10 mM succinate.
Results
The effect of increasing concentrations of carvedilol on Ca 2q rP -induced mitochondrial swelling was studied by i measuring the changes in the suspension absorbance at 540 nm in a sucrose-based media. Carvedilol protected heart mitochondria from the mitochondrial permeability transi-Ž . tion in a dose-dependent manner Fig. 1 . Fig. 2 shows that the addition of carvedilol to the mitochondrial suspension affected the magnitude of swelling in a time-dependent manner. Carvedilol, per se, neither stopped nor reversed the mitochondrial permeability transition but needed at least 3 min to have an inhibitory effect. To see whether this protection extended to the usually observed membrane depolarisation, we measured the variation in the mitochon-Ž . drial electric potential DC after the addition of calcium pulses. A representative recording is shown in Fig. 3 , where it can be seen that carvedilol did not have any supplemented with 4 mM rotenone, 0.5 mg oligomycin and 8 mM succinate. After a basal line was established, calcium was added. Where referred, carvedilol was pre-incubated with mitochondria for 3 min at Ž . Ž . 258C. The additions were as follows: A 1 mM cyclosporin A, B 20 Ž . Ž . Ž . mM carvedilol, C 10 mM carvedilol, D 5 mM carvedilol and E no additions. protective effect against calcium-induced depolarisation, whatever the concentration. Simultaneous recording of mitochondrial DC and swelling showed that although there was an inhibitory effect on mitochondrial swelling, Ž . no difference was observed in the DC data not shown .
This led us to propose that carvedilol caused a selective inhibition of the Ahigh-conductanceB state of the mitochondrial permeability transition pore. Sucrose, but not proton, influx would be prevented by carvedilol, with consequent membrane depolarisation.
This hypothesis was further corroborated by the measurement of mitochondrial swelling in a KCl-based media. supplemented with 4 mM rotenone, 0.5 mg oligomycin and 8 mM . succinate, right recording medium. Carvedilol was pre-incubated with mitochondria for 3 min.
We found out that 20 mM carvedilol had no effect on the Ž . magnitude of swelling Fig. 4 , right , which contrasts sharply with the effect of the same concentration of carvedilol in a sucrose-based media, where an inhibition is Ž . clearly visible Fig. 4 , left . Carvedilol even increased the rate of swelling in KCl-based media. This would mean that the entry of the larger molecule, sucrose, was restricted, in contrast to the entry of much smaller ions. In other words, carvedilol caused a selective exclusion of solutes. When media based on polyethyleneglycols with molecular weights 200 and 1000 were used, and despite an overall inhibitory effect against mitochondrial swelling, we noticed that the inhibition was more pronounced in the Ž . polyethyleneglycol -based media data not shown . 1000 Fig. 5 . Oxidation of mitochondrial protein thiol groups determined as Ž described in Section 2. Mitochondria were incubated with calcium 500 . Ž . mM for 3 min before the assays Ca and CV . When present, carvedilol Ž . CV was pre-incubated with mitochondria for 30 min before calcium addition. Media were the same as described in the legend of Fig. 1 The oxidation of protein thiol groups is known to be one of the hallmarks of induction of the mitochondrial permeability transition. We determined the extent of carvedilol-induced protection against protein thiol group oxidation. We found out that carvedilol decreased the extent of protein thiol group oxidation induced by Ca 2q rP . Measurements of calcium movements, using Arsenazo as a calcium sensitive probe, showed that carvedilol had a dual action on mitochondrial calcium accumulation: a negligible effect when calcium concentrations were below the Ž threshold for pore opening i.e., calcium uptake was nor-. Ž . mal Fig. 6 , down and a protective effect when the calcium concentration was enough to cause pore activation Ž . Fig. 6 , up . Thus, carvedilol increased the rate and extent of calcium accumulation at high calcium concentrations, demonstrating a protective effect, while not having any effect on calcium uptake at low calcium concentrations. These results showed that the decrease in mitochondrial DC was not enough to decrease calcium entry. Fig. 6 . Determination of extra-mitochondrial calcium movements using Arsenazo as a calcium-sensitive probe. Two millilitres of assay medium Ž200 mM sucrose, 10 mM EGTA-Tris, 5 mM KH PO , 10 mM Tris, pH 
Discussion
In this work, we studied the effect of carvedilol on the permeability transition in heart mitochondria, a deleterious event often associated with mitochondrial and cellular dysfunction.
As cardiac cells handle high concentrations of calcium, heart mitochondria are much more resistant to calcium than liver mitochondria, for example. In our work, it was necessary to use 5 mM P and 500 mM calcium or higher i to induce mitochondrial swelling and depolarisation. In liver mitochondria, the calcium concentrations used to induce mitochondrial permeability transition pore opening are usually five times lower. As cardiomyocytes need a constant supply of mitochondrial ATP to ensure their functions, their survival is threatened when mitochondrial dysfunction occurs. In a condition of ischemiarreperfusion, where there is increased oxidative stress, calcium and P , the mitochondrial permeability transition occurs i ŽCrompton and Costi, 1990; Halestrap et al., 1998; Baker . et al., 1988; Kristian and Siesjo, 1996 . The use of drugs tó protect cardiac cells from the mitochondrial permeability transition is most valuable in these situations.
In this work, we showed that carvedilol is an inhibitor of the mitochondrial permeability transition, exerting a Ž dose-dependent effect against mitochondrial swelling Fig. . Fig. 2 because it took up to 3 min to attain the maximum inhibitory effect. This lag time may correspond to the insertion of carvedilol into the mitochondrial membrane because carvedilol has a great Ž . tendency to insert into membranes Cheng et al., 1996 . The opening of the mitochondrial permeability transition pore occurred simultaneously with mitochondrial depolari-Ž . sation drop in DC . No protective effect of carvedilol against Ca 2q -induced depolarisation was observed when a TPP q -selective electrode was used. As seen in Fig. 3 , carvedilol was unable to maintain DC after a strong Ca 2q pulse. The only visible effect was a slight decrease in DC , Ž concomitant with a weak protonophoretic activity Oliveira . et al., 2000b . This was confirmed by results obtained with simultaneous recordings of mitochondrial DC and swelling, where inhibition was noticed in the swelling component but not in the DC depolarisation component.
Carvedilol was unable to inhibit mitochondrial swelling Ž . in a KCl-based media Fig. 4 but showed a stronger inhibitory effect in a polyethyleneglycol -based media 1000 than in a polyethyleneglicol -based media. This may 200 mean that carvedilol only inhibited one of the substrates of the mitochondrial permeability transition pore, the highconductance state, which is responsible for mitochondrial swelling in sucrose-based media. In other words, carvedilol probably inhibited the entry of large molecules into the mitochondrial matrix but had no effect on the entry of smaller molecules. In our opinion, this is the reason why we observed different degrees of protection induced by carvedilol according to the size of the external osmotically active molecules.
Carvedilol also inhibited the oxidation of mitochondrial Ž . protein thiol groups Fig. 5 , an event associated with opening of the mitochondrial permeability transition pore. Ž . As proposed by Zago et al. 2000 , the redox state of endogenous pyridine nucleotides and hence the redox state of mitochondrial thiols can determine the solute selectivity of the permeability transition pore. This may explain the different degrees of protection provided by carvedilol in sucrose and in KCl-based media, in spite of the observed similarity in inhibition of protein thiol group oxidation. The decrease in thiol group oxidation can be explained by Ž the antioxidant activity of carvedilol Yue et al., 1992a,b; . Moreno et al., 1998 . This agrees with results obtained ŽÄŽ w Ž .
x wŽ with BM910228 1-3-hydroxy-carbazolyl-4 -oxy -3-2-. x Ž .4. methoxyphenoxyethyl -amino -propanol-2 , a hydroxylated metabolite of carvedilol, that has greater antioxidant Ž . activity Yue et al., 1994 , which inhibited mitochondrial swelling in the sucrose-media to a greater extent than did Ž . carvedilol in the same concentrations data not shown .
Protection against thiol group oxidation may be the main mechanism by which carvedilol inhibits the mitochondrial permeability transition pore in its high conductance state. We also considered that carvedilol, due to its protonophoretic properties, might depress calcium influx into the mitochondria, thus inhibiting the permeability transition in an indirect form. Our results with the Arsenazo technique ruled out this hypothesis. Carvedilol not only did not have an inhibitory effect on calcium influx at Ž . low calcium loads Fig. 6 , down but it also inhibited mitochondrial calcium release induced by high calcium Ž . loads Fig. 6, up . On the basis of our results, we propose that carvedilol may act as a selective inhibitor of the high-conductance state of the mitochondrial permeability transition pore, as Ž described previously Ichas et al., 1994 Ichas et al., , 1997 Ichas and . Ž Mazat, 1998 , or, as proposed in some models Petronilli et . al., 1999 , as an inhibitor of the long lasting pore opening responsible for the observed extensive swelling in the sucrose-based media.
Since the low-conductance state of the mitochondrial permeability transition pore has been associated with protective mechanisms against calcium overload, oxidative Ž stress and DC hyperpolarisation Ichas and Mazat, 1998; . Huser and Blatter, 1999 , it is possible that the cardioprotective action of carvedilol is, partly, due to a selective inhibition of a deleterious high-conductance state of the mitochondrial permeability transition pore, without inhibiting the low-conductance state of the pore, which is considered to have physiological functions. Work is underway in our laboratory to determine the precise mechanism of carvedilol actions and to identify the components of the ( )mitochondrial permeability transition event. This is very important in order to explain some results that appeared in the literature concerning non-conventional, mitochondrial Ž permeability transitions Sokolove and Haley, 1996; . Kushnareva and Sokolove, 2000 . In the future, we are also interested in finding out whether carvedilol actually binds to a mitochondrial protein that forms the pore.
In conclusion, we propose that carvedilol is an inhibitor of the high-conductance state of the mitochondrial permeability transition pore, acting on mitochondrial swelling and calcium efflux without preventing DC depolarisation or swelling in a ionic media. With regard to the clinical relevance of the finding, although carvedilol is not able to prevent mitochondrial DC depolarisation, it might prevent structural damage to the mitochondria. The antioxidant activity of carvedilol may help prevent the irreversible mitochondrial dysfunction caused by the permeability transition. Ž tion for Science and Technology PRAXIS XXIrBDr 21494r99 and PRAXIS XXIrBDr21454r99, respec-. Ž tively . We are grateful to Prof. Alicia Kowaltowski Saõ . Paulo University, Brazil for valuable discussions and to Ž Dr. Lino Gonçalves Cardiology Service-University of . Coimbra for kindly providing us carvedilol.
